Is safinamide useful for atypical Parkinsonian syndromes?
Objective: Seeking new treatment strategies in atypical Parkinsonian syndromes Background: Atypical parkinsonian syndromes (APS) include several entities leading to parkinsonism with atypical features such as…Comparative study of the cognitive and behavioral disturbances between progressive supranuclear palsy phenotypes
Objective: Explore cognitive and behavioural disturbances between subtypes of progressive supranuclear palsy (PSP). Background: Although clinical diagnosis of PSP is based on specific motor symptoms,…Association of impaired melatonin secretion with sleep disturbance in multiple system atrophy
Objective: To clarify whether there is impaired melatonin secretion and whether it is associated with sleep disturbance in patients with multiple system atrophy (MSA). Background:…Affective impairment and emotional tone of early Richardson’s syndrome and Progressive Supranuclear Palsy with predominant parkinsonism: The role of Alexithymia and Anhedonia
Objective: To define qualitative and quantitative differences of alexithymia and anhedonia among Progressive Supranuclear Palsy (PSP) with predominant parkinsonism (PSP-P), Richardson’s syndrome (PSP-RS) and Parkinson’s…Immunological causes of atypical parkinsonism
Objective: To study the clinical and biochemical features of atypical parkinsonism. Evaluate results of the immune-mediated treatment Background: Atypical parkinsonism is a heterogeneous group of…The role of deep brain stimulation targeting GPi in patients with multiple system atrophy
Objective: To report clinical outcomes of two patients diagnosed with MSA-P who underwent bilateral deep brain stimulation (DBS). Background: The role of DBS in patients…PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy
Objective: To evaluate PBT434 in a transgenic mouse model of multiple system atrophy (MSA) Background: PBT434 is a novel quinazolinone inhibitor of iron-mediated protein accumulation…Cerebrospinal fluid levels of cytokines in multiple system atrophy: A cross-sectional study of the atalan msa registry (CMSAR)
Objective: To compare the cerebrospinal fluid (CSF) levels of 38 cytokines in multiple system atrophy (MSA) patients vs. control and Parkinson’s disease (PD) subjects. Background:…The Catalonian Multiple System Atrophy Registry (CMSAR): The motor features and their impact on disability status in MSA patients
Objective: To assess motor symptoms and their demographic correlates in MSA patients included in the CMSAR as well their impact on daily living activities. Background:…Corticobasal Syndrome: A Single Center Case Series
Objective: To evaluate clinical features of corticobasal syndrome in a tertiary care setting. Background: None. Methods: A retrospective chart review was done. All patients diagnosed…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.